Last reviewed · How we verify
A: Peg-interferon alpha-2a & Ribavirin
At a glance
| Generic name | A: Peg-interferon alpha-2a & Ribavirin |
|---|---|
| Also known as | Pegasys & Robatrol |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
- Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (PHASE2)
- Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) (PHASE2)
- A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) (PHASE2)
- A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures (PHASE1, PHASE2)
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV (PHASE3)
- A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: